Ava John-Baptiste, PhD

Dr.John-BaptisteAssistant Professor
P: 519.661.2111 ext: 86265
Email: ajohnbap@uwo.ca

Dr. John-Baptiste conducts research on the safety, effectiveness and cost-effectiveness of health technologies. She is a health economist in the Centre for Medical Evidence, Decision Integrity and Clinical Impact (MEDICI). Through MEDICI, her research supports health policy decision-making at the London hospitals. Dr. John-Baptiste also teaches health economics in the Schulich Interfaculty Program in Public Health.

The field of health technology assessment has many opportunities. Individuals with undergraduate training in mathematics, statistics, engineering or computer science are well equipped to contribute to applied and methodological research in this area. Those interested in pursuing graduate studies in this area are encouraged to contact Dr. John-Baptiste via e-mail.

Appointments

Research Cluster Membership

Research Interests

  • Cost-analysis and cost-reduction in the hospital setting
  • Economic evaluation of health technologies
  • Decision analytic modeling and simulation
  • Bayesian approaches to evidence synthesis
  • Disinvestment in technologies of low or uncertain value

Recent Research Grants

  • Economic evaluation of early intervention for mood and anxiety disorders (Lawson Health Sciences Research Institute, Internal Research Fund)
  • Clinical impact of disinvestment in hydroxyethyl starches for patients undergoing cardiac surgery (Department of Anesthesia & Perioperative Medicine, Schulich School of Medicine & Dentistry, Western University)
  • Estimating the risk of adverse drug events using Bayesian evidence synthesis (Canadian Institutes of Health Research, Drug Safety and Effectiveness Network)

Publications (selected)

  • John-Baptiste A, Sowerby LJ, Chin CJ, Martin J, Rotenberg BW. Comparing surgical trays with redundant instruments with trays with reduced instruments: a cost analysis. CMAJ Open. 2016 Aug 12;4(3):E404-E408. doi: 10.9778/cmajo.20150092.
  • John-Baptiste A, Schapira MM, Cravens C, Chambers JD, Neumann PJ, Siegel J, Lawrence W. The Role of Decision Models in Health Care Policy: A Case Study. Med Decis Making. 2016 Jul;36(5):666-79. doi: 10.1177/0272989X16646732. PMID: 27225487.
  • Chin CJ, Sowerby LJ, John-Baptiste A, Rotenberg BW. Reducing otolaryngology surgical inefficiency via assessment of tray redundancy. J Otolaryngol Head Neck Surg. 2014;43(1):46. Epub 2014 Dec 3.
  • John-Baptiste A, Wu W, Rochon P, Anderson GM, Bell CM. A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer. PLoS One. 2013 May 6;8(5):e62614.
  • John-Baptiste A, Yeung MW, Leung V, van der Velde G, Krahn M. Cost-effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review. Pharmacoeconomics. 2012 Nov 1;30(11):1015-34.
  • Lapointe-Shaw L, Fischer HD, Newman A, John-Baptiste A, Anderson GM, Rochon PA, Bell CM. Potential savings of harmonising hospital and community formularies for chronic disease medications initiated in hospital. PLoS One. 2012;7(6):e39737. Epub 2012 Jun 26.
  • John-Baptiste A, Bell C. A glimpse into the black box of cost-effectiveness analyses. CMAJ. 2011 Apr 5;183(6):E307-8. Epub 2011 Mar 14.
  • John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol. 2010 Aug;53(2):245-51.Epub 2010 May 11.
  • John-Baptiste A, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, Yoshida EM, Anderson FH, Krahn MD. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009 Oct;104(10):2439-48. doi: 10.1038/ajg.2009.346. PMID: 19568230.